| ASQGX | VSMAX | ASQGX / VSMAX | |
| Total Expense Ratio | 0.65 | 0.05 | 1,300% |
| Annual Report Gross Expense Ratio | 0.65 | 0.05 | 1,300% |
| Fund Existence | 9 years | 25 years | - |
| Gain YTD | 12.840 | 9.638 | 133% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 3000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 160M | 163B | 0% |
| Annual Yield % from dividends | 0.47 | 1.32 | 35% |
| Returns for 1 year | 10.73 | 7.57 | 142% |
| Returns for 3 years | 43.65 | 45.14 | 97% |
| Returns for 5 years | 14.05 | 36.24 | 39% |
| Returns for 10 years | N/A | 142.15 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GEMQX | 15.13 | 0.09 | +0.60% |
| Goldman Sachs Emerging Mkts Eq ex. Chn R | |||
| VVOCX | 20.83 | 0.03 | +0.14% |
| Invesco Value Opportunities C | |||
| RSIGX | 18.03 | 0.02 | +0.11% |
| Victory RS International Y | |||
| WPGSX | 11.55 | 0.01 | +0.09% |
| WPG Partners Select Small Cap Value Ins | |||
| ETNHX | 51.39 | -0.39 | -0.75% |
| Eventide Healthcare & Life Sciences N | |||